Cited by 704Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryRNA Interference and Gene Delivery

A comprehensive overview of exosomes as drug delivery vehicles — Endogenous nanocarriers for targeted cancer therapy

Johnsen, Kasper Bendix, Gudbergsson, Johann Mar, Skov, Martin Najbjerg, Pilgaard, Linda, Moos, Torben, Duroux, Meg·2014·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Abstract

Exosomes denote a class of secreted nanoparticles defined by size, surface protein and lipid composition, and the ability to carry RNA and proteins. They are important mediators of intercellular communication and regulators of the cellular niche, and their altered characteristics in many diseases, such as cancer, suggest them to be important both for diagnostic and therapeutic purposes, prompting the idea of using exosomes as drug delivery vehicles, especially for gene therapy. This review covers the current status of evidence presented in the field of exosome-based drug delivery systems. Components for successful exosome-based drug delivery, such as choice of donor cell, therapeutic cargo, use of targeting peptide, loading method and administration route are highlighted and discussed with a general focus pertaining to the results obtained in models of different cancer types. In addition, completed and on-going clinical trials are described, evaluating exosome-based therapies for the treatment of different cancer types. Due to their endogenous origin, exosome-based drug delivery systems may have advantages in the treatment of cancer, but their design needs further refinement to justify their usage on the clinical scale.

Integrity signals

Registry

Crossref · 10.1016/j.bbcan.2014.04.005

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • High biocompatibility and low immunogenicity of exosomes enhance their uptake profile, stability in systemic circulation, and in vitro and in vivo therapeutic efficacy.

    “Furthermore, their high biocompatibility and low immunogenicity enhance their uptake profile, their stability in systemic circulation, and their in vitro and in vivo therapeutic efficacy [229,230].”

Cites

1 retracted

Flagged first, then by citations

1 of the 125 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M.
Affiliations
Aalborg University (DK)
Corresponding author
Duroux, Meg
Venue
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Publisher
Elsevier BV
Published
2014-08
Volume
1846
Issue
1
Pages
75-87
ISSN
0304-419X (ISSN-L)
OpenAlex
W2151079805
Cited by
704
References
125
Citations by year
2026: 16 · 2025: 45 · 2024: 51 · 2023: 60 · 2022: 63 · 2021: 69 · 2020: 77 · 2019: 78 · 2018: 82 · 2017: 76 · 2016: 46 · 2015: 34 · 2014: 6 · 2012: 1
FWCI
5.08
Type
journal article
Language
en
Open access
closed
Locations
  • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Funders
  • Harboefonden (839070)
  • Spar Nord Fonden (839071)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
exosomes, exosome-based drug delivery, targeted cancer therapy, gene therapy, intercellular communication, targeting peptides, route of administration, clinical trials, cancer
MeSH terms
Animals, Antineoplastic Agents, Drug Carriers, Humans, Neoplasms, Pharmaceutical Vehicles, Nanoparticles, Exosomes, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review